Find Clinical Trials

Inclusion Criteria: * • Aged \>18 years * Cirrhotic patients with arterial hypertension * Endoscopic evidence of medium/large-sized esophageal varices Exclusion Criteria: * • History of variceal bleeding or previous primary prevention of varices. * Portal vein thrombosis or previous porto-systemic shunts as TIPS. * Patients on drugs affecting portal pressure (beta blockers, nitrates). * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, severe bradycardia. * Patients with severe respiratory diseases (COPD, bronchial asthma). * Uncontrolled diabetes mellitus * Renal impairment * Hepatocellular carcinoma * Allergy to carvedilol * Pregnancy or lactation

Inclusion Criteria: Clinical diagnosis of breast cancer Exclusion Criteria: Missing pathology Missing follow-up results Missing data

Inclusion Criteria: * Patients 18 years or older * Diagnosis of non-metastatic breast cancer * Intended to receive radiation therapy to the breast/chest-wall and regional lymph nodes * Ability to communicate in English without assistance of another person * Ability to provide informed consent Exclusion Criteria: * Commenced any radiation therapy-specific procedures (e.g. education, CT-simulation, etc.) * Received a previous course of radiation therapy

Inclusion Criteria: * Female patient with unilateral invasive breast cancer and cN1-3 * Pathologically proven positive axillary lymph node * Planned to undergo neoadjuvant chemotherapy (± immunotherapy), followed by staging and treatment of the breast and axilla Exclusion Criteria: * Clinically node negative breast cancer before NST * Bilateral invasive breast cancer * Neoadjuvant endocrine therapy * Distant metastases (including oligometastatic disease) * History of invasive breast cancer * Other malignancies, except for basal/squamous cell skin cancer, and in situ carcinoma of the cervix or breast * Axillary surgery or radiotherapy before NST (this includes SLNB prior to NST)

Inclusion Criteria: 1. Pregnant women with \<20 weeks of gestation 2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center 3. Permanent residents or families intended to remain in Guangzhou with their child for more than 3 years Exclusion Criteria: 1. Combined with heart disease, hypertension, diabetes or hyperthyroidism 2. Taking anti-depressants and other treatments for depression 3. Participants was in infection status when the biological samples were collected

Inclusion Criteria: * Aged within 18 and 80 years; * Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury; * ICP monitoring started for clinical indication and accordingly to local policies * ICP device connected to the Integra CereLink ICP monitor. Exclusion Criteria: * ICP monitoring not inserted * No availability of the Integra CereLink ICP monitor.

Inclusion Criteria: * Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol * Patients must have a PIK3CA mutation as determined via the MATCH Master Protocol * Patients must have an electrocardiogram (ECG) within 8 weeks prior to treatment assignment and must have no clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block) * Patients with known left ventricular dysfunction must have echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 4 weeks prior to registration to treatment and must not have left ventricular ejection fraction (LVEF) \< institutional lower limit of normal (LLN). If the LLN is not defined at a site, the LVEF must be \> 50% for the patient to be eligible * Patients must have a fasting glucose =\< 125 mg/dL * NOTE: Please provide clear documentation that the glucose test was conducted at a fasting state * Patients with prior treatment with an mTOR inhibitor are acceptable. These include, but are not limited to: temsirolimus, everolimus, ridaforolimus, sirolimus, CC-223, MLN128 (INK128), DS-3078, CC-115, AZD-2014, AZD8055 Exclusion Criteria: * Patients must not have known hypersensitivity to GDC-0032 (taselisib) or compounds of similar chemical or biologic composition * Patients must not have breast cancer * Patients with squamous cell carcinoma of the lung who have PIK3CA mutations who have access to AND are eligible for Lung-MAP (S1400) are not eligible * Patients must not have KRAS mutations, and/or PTEN mutation or loss, detected in the tumor sample as determined by the MATCH screening assessment. PTEN loss will be determined by immunohistochemistry * Patients must not have had prior therapy with a PI3K inhibitor or PI3K/mTOR inhibitor. These include, but are not limited to: BEZ235, XL-765 (SAR245409), GDC-0980, PF-04691502, PF-05212384 (PKI-587), SF-1126, GSK 2126458, P-7170, BGT-226, LY3023414, GDC-0084, DS-7423, BKM-120 (buparlisib), PX-866, XL-147, GDC-0941 (pictilisib), VS-5584, BAY-80-6946, ZSTK-474, WX 037, AZD8835, GSK2636771, GS-9820, BYL719, MLN1117 (INK1117), idelalisib, TGR1202, RP6530, duvelisib (IPI-145), CUDC-907. Prior GDC-0032 (taselisib) is not allowed * Patients must not have had prior therapy with an Akt inhibitor. These include, but are not limited to: MK-2206, GSK690693, AZD5363, triciribine, perifosine, GSK2141795, GSK2110183, SR13668, BAY1125976, GDC-0068 (ipatasertib), LY2780301, ARQ092 * Patients must not have type 1 or 2 diabetes requiring anti-hyperglycemic medication (e.g. metformin, glipizide, insulin) * Patients must not have current dyspnea at rest or require any daily supplemental oxygen * Patients must not have history of inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g. diverticulitis)

Inclusion Criteria: 1. Age 8-11 years-old 2. Good general health 3. BMI≥85th percentile Exclusion Criteria: 1. Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion 2. Diagnosis of T2DM and/or presence of other endocrinologic disorders leading to obesity (e.g., Cushing Syndrome) 3. Current or past anti-psychotic drug use that would affect metabolism 4. Non-diet treatment for hypertension or dyslipidemia 5. Precocious puberty and/or receiving androgen and estrogen therapy 6. Medication use known to affect body composition/weight

Inclusion Criteria: * A patient who has been diagnosed with breast cancer and has been scheduled for a first cycle of anthracycline therapy. * Participant who is willing and able to give informed consent for participation in the study. * Healthy (gender and age matched) volunteers willing to give informed consent for participation in the study. Exclusion Criteria: * Contraindication to magnetic resonance scanning such as an implantable cardiac device.

Inclusion Criteria: Men and women age ≥ 18 years old (unless otherwise specified) Willing and able to provide written informed consent/assent ECOG Performance Status 0 - 1 Patients with: Newly diagnosed breast cancer with tumor size \< 5 cm who are not eligible for I-SPY2 (to prevent recruitment competition), or not recommended to undergo standard of care neoadjuvant chemotherapy with at least one of the following features: * Triple negative breast cancer (TNBC) defined using the ASCO CAP guidelines with the following modification supported by a recent publication as ER ≤ 10%, PR ≤ 10%, HER2- determined by immunohistochemistry and/or fluorescence in situ hybridization analyses and with tumor size ≤ 2.5 cm; * HR+ HER2- breast cancer regardless of nodal status and age of diagnosis ≥ 50 * HR+ HER2- breast cancer and age of diagnosis \<50 with tumor size ≤ 2.5 cm and clinically node (+) * HR+ or HR- and HER2+ breast cancer with tumor size ≤ 2.5 cm * Ductal carcinoma in situ (DCIS) with microinvasion OR * Locally recurrent breast cancer of any receptor subtype with no prior radiation, not recommended to receive neoadjuvant chemotherapy and expecting surgical excision as part of treatment. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2 of the study protocol OR 2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120 days for study treatments with risk of genotoxicity after the last dose of study treatment. * Female participants of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Medically accepted methods of birth control include a diaphragm, cervical cap, latex condoms, surgical sterility, intrauterine devices (IUDs), hormonal implants, injectable contraceptives, or birth control pills. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year. * Ability to tolerate radiation therapy (e.g., lie flat and hold position) * Demonstrate adequate hematologic, renal, hepatic, thyroid, and bone marrow function Inclusion Criteria: * Men and women age ≥ 18 years old (unless otherwise specified) * Willing and able to provide written informed consent/assent * ECOG Performance Status 0 - 1 * Patients with: * Newly diagnosed breast cancer with tumor size \< 5 cm who are not eligible for I-SPY2 (to prevent recruitment competition), or not recommended to undergo standard of care neoadjuvant chemotherapy with at least one of the following features: * Triple negative breast cancer (TNBC) defined using the ASCO CAP guidelines with the following modification supported by a recent publication as ER ≤ 10%, PR ≤ 10%, HER2- determined by immunohistochemistry and/or fluorescence in situ hybridization analyses and with tumor size ≤ 2.5 cm; * HR+ HER2- breast cancer regardless of nodal status and age of diagnosis ≥ 50 * HR+ HER2- breast cancer and age of diagnosis \<50 with tumor size ≤ 2.5 cm and clinically node (+) * HR+ or HR- and HER2+ breast cancer with tumor size ≤ 2.5 cm * Ductal carcinoma in situ (DCIS) with microinvasion OR * Locally recurrent breast cancer of any receptor subtype with no prior radiation, not recommended to receive neoadjuvant chemotherapy and expecting surgical excision as part of treatment. • A female participant is eligible to participate if she is not pregnant (see Appendix 2), not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 2. OR 2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 2 during the treatment period and for at least 120 days for study treatments with risk of genotoxicity after the last dose of study treatment. • Female participants of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Medically accepted methods of birth control include a diaphragm, cervical cap, latex condoms, surgical sterility, intrauterine devices (IUDs), hormonal implants, injectable contraceptives, or birth control pills. Participants of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \> 1 year. * Ability to tolerate radiation therapy (e.g., lie flat and hold position) * Demonstrate adequate hematologic, renal, hepatic, thyroid, and bone marrow function Exclusion criteria: • A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. • A history of prior radiotherapy to the ipsilateral breast/chest wall that precludes delivery of hypofractionated radiotherapy. • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137). • Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks • Has not adequately recovered from major surgery or has ongoing surgical complications • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. • Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid) • Participants with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Participants that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Participants with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study. Steroid prep due to dye allergies prior to staging scans or use in anti-emetic prophylaxis is allowed. • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease. • Has an active infection requiring systemic therapy. • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. * Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). * Has a known history of Hepatitis B (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (defined as HCV RNA \[qualitative\] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority. • Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study interve

Inclusion Criteria: * Asthma diagnosis according to GINA / ATS guidelines. * Age ≥18 years Exclusion Criteria: •cognitive impairment

Inclusion Criteria: * Patients with solid tumors (either 3+ by immunohistochemistry or with evidence of gene amplification (\>2.0) by fluorescence in situ hybridization (FISH)) * At least 18 years of age * Able to provide informed consent. Karnofsky score greater than 50 * Females of childbearing potential must have a negative pregnancy test at screening/baseline * AIP-301 Ga-68 positive scan define by SUV greater than 10. * Adequate organ function, defined as: 1. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. 2. Hemoglobin (Hb) ≥9 g/dl (transfusion or use of EPO is permitted). 3. Platelets \> 100,000/mm3 4. Creatinine ≤ 1.5 x normal value based on the Cock Gault (CG) equation. 5. AST or ALT ≤ 2.5 x ULN (or ≤5 x ULN in case of liver metastasis) 6. Alkaline phosphatase ≤2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN. 7. Total bilirubin ≤1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome). Baseline LVEF ≥50% measured using echocardiogram or equilibrium isotopic ventriculography (MUGA). Exclusion Criteria: * • Serum creatinine \>3.0 mg/dL (270 μM/L) * Hepatic enzyme levels more than 5 times upper limit of normal. * Known severe allergy or hypersensitivity to IV radiographic contrast. * Use of any other investigational product or device within 30 days prior to dosing or known requirement for any other investigational agent prior to completion of all scheduled study assessments. * Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result. * Inability to lie still for the entire imaging time (e.g. cough, severe arthritis, etc.). * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Recognized concurrent active infection (e.g., HIV) * Previous Grade 3 or higher allergic reaction to Trastuzumab that resulted in discontinuation of Trastuzumab therapy. Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance. * Adult patients who require monitored anesthesia for PET scanning

Inclusion Criteria: 1. Age ≥18 years 2. Female or male 3. Invasive carcinoma of the breast 4. Breast conserving surgery(BCS) with axillary clearance or total mastectomy with axillary clearance(TMAC); (reconstruction allowed but not with implant; tissue expanders with distant metal ports are allowed) 5. Concurrent trastuzumab and hormone therapy is allowed 6. Axillary staging and/or dissection 7. Complete microscopic excision of primary tumour 8. pT3-4pN2-3 M0 disease 9. Clinical stage III disease or pathological node positive if they have received neo-adjuvant chemotherapy. 10. Written informed consent 11. Able to comply with follow-up Exclusion Criteria: 1. Supraclavicular node or internal mammary node or distant metastasis 2. Past history of malignancy except (i) basal cell skin cancer and CIN cervix uteri or(ii) non-breast malignancy allowed if treated with curative intent and at least 5 years disease free 3. Contralateral breast cancer, including DCIS, irrespective of date of diagnosis 4. Breast reconstruction using implants 5. Pregnancy 6. Concurrent cytotoxic chemotherapy(sequential neoadjuvant or adjuvant cytotoxic therapy allowed)

Inclusion Criteria: * early-stage invasive breast cancer positive for estrogen receptor and / or progesterone receptor is pathologically confirmed; * patients who have completed standard endocrine therapy for 5 years without recurrence and metastasis; * 18-70 years old; * patients with one of the following six manifestations: KI67 ≥ 30%; tumor size \> 2 cm; positive lymph nodes; histological grade III; vascular cancer thrombus; HER-2 gene overexpression or amplification. Exclusion Criteria: * with a history of other malignancies; * patients who have severe abnormalities in important organs, such as the heart, liver, and kidney or who cannot be tolerant to extended treatment due to poor constitution; * patients with severe osteoporosis or dyslipidemia, or those who cannot tolerate endocrine therapy ; * patients who have participated in other clinical trials.

Inclusion Criteria: * Insertion of TIPS according to guidelines Exclusion Criteria: * Contraindication for TIPS

Inclusion Criteria: * eligible for bariatric surgery according to NICE guidelines (GC 189) * Type 2 diabetes mellitus * BMI \>30kg/m2 Exclusion Criteria: * Recent hospitalisation in the past 30 days * Recurrent hypoglycaemic episodes * Recurrent hypotensive episodes * Contraindications to bariatric surgery * Previous bariatric surgery * Current pregnancy * Breastfeeding

Inclusion Criteria: * Pathologically confirmed residual invasive breast cancer, in the breast and/or lymph node(s), following neoadjuvant chemotherapy. In the absence of residual invasive disease in the breast, lymph node must contain at least 2mm of invasive disease. * HER2 negative in primary tumor pre-treatment by local pathology assessed according to current ASCO/CAP guidelines: * In situ hybridization non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), OR * Immunohistochemistry (IHC) 0 or IHC 1+. * NOTE: If more than one test result is available and not all results meet the inclusion criterion definition, all results should be discussed with the Principal Investigator to establish eligibility * ER and PR negative in primary tumor pre-treatment defined as \< 10% of cells expressing hormonal receptors via IHC analysis by local laboratory assessment. * Patients must have received neoadjuvant chemotherapy prior to breast surgery. * Patients must be within 4 months of completion of all locoregional therapy (either last surgery or last dose of radiation, whichever is later) . Definitive breast surgery must have been performed and includes lumpectomy or mastectomy with pathologically clear margins (i.e. no ink on tumor). For patients undergoing lumpectomy, this must be followed by whole breast irradiation. Definitive surgery also includes axillary surgery, either sentinel lymph node biopsy or axillary lymph node dissection at the discretion of the attending surgeon. * Evidence of ctDNA in blood sample collected after completion of all local and systemic neoadjuvant therapy (preoperative chemotherapy, surgery and radiation), confirmed by central testing. Detection of any tumor specific mutations (TSMs) within the sample will be considered positive for purposes of study eligibility. * Concurrent receipt of bone modifying agents (bisphosphonates or rank-ligand inhibitors)is allowed. * Prior treatment with an immune checkpoint inhibitor in the neoadjuvant setting is permitted. * ECOG Performance Status of 0 or 1 * Men and women, age ≥ 18 years * Adequate hematologic and organ function defined by the following: * ANC ≥ 1.5 × 109/L (1500/μL) without granulocyte colony-stimulating factor support * WBC count ≥ 2.5 × 109/L (2500/μL) * Absolute Lymphocyte count ≥ 0.5 × 109/L (500/μL) * Platelet count ≥ 100 × 109/L (100,000/μL) * Hemoglobin ≥ 90 g/L (9.0 g/dL), with or without transfusion * AST, ALT, and alkaline phosphatase (ALP) ≤ 2.5 × institutional upper limit of normal (ULN). * Serum bilirubin ≤ 1.5 × institutional ULN with the following exception: * Patients with known Gilbert syndrome: serum bilirubin level ≤ 3 × institutional ULN * Serum creatinine \< 1.5 x institutional ULN * Creatinine clearance ≥30 mL/min as assessed by the Cockcroft-Gault equation * Serum albumin ≥ 25 g/L (2.5 g/dL) * For patients not receiving therapeutic anticoagulation: INR or aPTT ≤ 1.5 × institutional ULN * For patients receiving therapeutic anticoagulation: stable anticoagulant regimen * Women of childbearing potential (pre-menopausal) must have a negative serum or urine pregnancy test within 7 days prior to start of therapy. A woman is defined as premenopausal if she is less than 12 months from last menstrual period with no identified cause other than menopause (medication induced amenorrhea is not acceptable). Pregnancy test is not required in women who are surgically sterile via bilateral salpingooophorectomy or hysterectomy. * Women of childbearing potential and men must agree to use adequate contraception for the duration of protocol treatment and for 6 months after last dose of atezolizumab and 6 months after last dose of sacituzumab govitecan, whichever is later. Hormonal contraceptives are not acceptable (see section 5.6). * Ability to understand and the willingness to sign a written informed consent document. Non-English speakers are eligible to participate but will be excluded from surveys/questionnaires unless the participant has a proxy available for translation. Exclusion Criteria: * Prior therapy with sacituzumab govitecan, irinotecan, or any topoisomerase I-containing antibody-drug conjugates at any time for early stage disease. * Receipt of adjuvant chemotherapy (all chemotherapy prior to registration must have occurred in the preoperative setting) * Prior hypersensitivity to atezolizumab or the excipients of atezolizumab or sacituzumab govitecan * Clinical or radiographic evidence of metastatic disease * Residual DCIS or LCIS alone without invasive cancer OR pT0N0i and pT0N1mic residual disease * Concurrent enrollment on another investigational therapy trial * Prior treatment-related toxicity must be resolved to ≤ Grade 1 prior to study enrollment with the exception of alopecia and peripheral neuropathy, prior to study enrollment. * Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study * Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study. * Intercurrent illness including, but not limited to: ongoing or active infection requiring systemic therapy, active tuberculosis, serious liver disease such as cirrhosis, active bleeding diathesis, uncontrolled Type I or Type II diabetes mellitus, Grade ≥ 2 uncontrolled or untreated hypercholesterolemia, Hypertriglyceridemia or hypercalcemia * Cardiovascular disease including: congestive heart failure of New York Heart Association Class III or IV, myocardial infarction (\<6 months prior to enrollment) unstable angina pectoris, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease, in the opinion of the investigator * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted. * Active (acute or chronic) autoimmune disease of any type except hypothyroidism on a thyroid-replacement hormone, celiac disease, or well-controlled psoriasis, eczema, lichen simplex chronicus or vitiligo. * Impairment of gastrointestinal function or active gastrointestinal disease that may significantly alter the absorption of the study agents (e.g., ulcerative disease, uncontrolled nausea(\> grade 2), vomiting (\> grade 2), diarrhea (\> grade 2), malabsorption syndrome or small bowel resection). * Congenital long QT syndrome or screening QT interval corrected through use of Fridericia's formula \>480 ms. * Participants known to be positive for the human immunodeficiency virus (HIV), Hepatitis B antigen (HepBsAg), or Hepatitis C virus (HCV) RNA are ineligible. * History of prior invasive breast cancer in either breast. * Participants with history of prior malignancy other than breast cancer are eligible if they have been disease-free for at least 5 years prior to enrollment with the exception of patients with thyroid cancer that has been definitively treated without spread to regional lymph nodes. * Treatment with strong strong UGT1A1 inhibitor or inducer within 4 weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study drug. * Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine while on protocol treatment * Known allergy or hypersensitivity to any of the study drugs or any of their excipients, including chimeric or humanized antibodies or fusion proteins and Chinese hamster ovary cell products or recombinant hu

Inclusion Criteria: * Written informed consent. * Age between 12 and 65, both genders. * Subjects with a confirmed clinical history of inhalant allergy (intermittent or persistent moderate-severe rhinitis and/or rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent mild-moderate controlled asthma according to the GEMA 5.0 definition) caused by allergy to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent. * Subjects with a positive skin prick-test wheal size \>5 mm higher diameter due to Dermatophagoides pteronyssinus and/or Dermatophagoides farinae. The positive and negative control of the test should give consistent results. The results will be valid 12 months prior to the signing of the informed consent. * Specific immunoglobulin E against house dust mites \>3,5 KU/mL (InmunoCAP® o Immulite), for the complete extract of Dermatophagoides pteronyssinus and / or for Dermatophagoides farinae or for some of the molecular components of these allergenic sources * Subjects should preferably be monosensitized to the study allergens. In case of subjects sensitized to other aeroallergens, only those with the following characteristics may be included in the study: * Subjects with positive skin test to Blomia tropicalis and Lepidoglyphus destructor, whose specific IgE values do not exceed or equal the values for the study allergens. The maximum specific IgE value for these allergens is 3.5 KU/L. * Subjects with positive skin tests to epithelia, as long as they present occasional exposure and symptomatology. * Subjects with positive skin tests to pollens, whose specific IgE values do not exceed or equal the values of the allergens in the study and who do not present exacerbations during the pollen season. The maximum value of specific IgE for these allergens is 17.5 KU/L. * Subjects with negative skin test for fungi * Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial, before the first administration of the IMP. * Women of childbearing age participating in the trial must agree to use an appropriate method of contraception, meaning any act, device, or medication to prevent conception or viable pregnancy, during the trial if they are sexually active. * Subjects with a diagnosis of asthma according to the GEMA 5.0 guideline. * Subjects capable of complying with the dosing regimen. * Subjects who own an smartphone for symptom registration and medication Exclusion Criteria: * Subjects who have received previous immunotherapy in the previous 5 years to dander, fungi, and mites. * Subjects in whom immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee. * Subjects with persistent severe or uncontrolled asthma, with an FEV1\<70% of baseline despite adequate pharmacological treatment at the time of inclusion in the trial. Also subjects with intermittent or persistent rhinitis/rhinoconjunctivitis with severe symptoms in whom oral or systemic antihistamine therapy is contraindicated. * Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test. * Subjects under treatment with β-blockers. * Clinically unstable subjects at the time of inclusion in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.). * Subjects with chronic active urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin prick test will be performed, or a history of hereditary angioedema. * Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor impairment, uncontrolled diabetes, malformations, multiple surgeries, nephropathy). * Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies. * Subject whose condition prevents him/her from offering cooperation and/or who has serious mental illness. * Subjects with a known allergy to other components of the investigational medicinal product other than the allergen. * Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis. * Direct investigator's relatives. * Pregnant women or breastfeeding women.

Inclusion Criteria: * Planned primary surgery for suspicious or verified breast malignancy Age of 18 years and above Signed informed consent Exclusion Criteria: * Planned neoadjuvant therapy On-going pregnancy Iodinated contrast agent allergy Renal failure (abnormal S-creatinine) Untreated thyreotoxicosis Severe heart failure Myastenia gravis Breast implant Local recurrence as index lesion Inability to understand and comprehend oral and written information of the study

Inclusion Criteria: * Disease indication * Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part). * Non-small cell lung cancer (NSCLC) * Head and neck squamous cell cancer (HNSCC) * Advanced HER2-negative breast cancer * Esophageal squamous cell carcinoma (ESCC) * Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ) * Cutaneous squamous cell cancer (cSCC) * Exocrine pancreatic adenocarcinoma * Bladder cancer * Cervical cancer * Gastric cancer * High grade serous ovarian cancer (HGSOC) * Part A only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options. * Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a PD-1/PD-(L)1 inhibitor, if applicable and available. * Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or \[neo\]adjuvant therapy is allowed). * Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy. * Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows: * Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used. * Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy * An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Measurable disease per the RECIST v1.1 at baseline Exclusion Criteria * History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death. * Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they: * are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment, * have no new or enlarging brain metastases, and * are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug. * In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids. * Carcinomatous meningitis * Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6 * Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts * Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin. * Routine antimicrobial prophylaxis is permitted * Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from clinically significant pulmonary illnesses * Part C and D: Prior therapy with a PD-1 inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE). * History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening * Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for hemoglobin) \<50% predicted * Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.